002821 Asymchem Laboratories(Tianjin)Co.,Ltd.
Closed 04-21 15:00:00
111.33
-2.39
-2.10%
High115.48Low111.00Vol6.39M
Open113.55D1 Closing113.72Amplitude3.94%
Mkt Cap40.19BTradable Cap35.29BTotal Shares361.00M
T/O718.00MT/O Rate2.02%Tradable Shares317.00M
P/B2.33ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Asymchem Laboratories Profit Rises 19% in 2025
MT Newswires Live  ·  12:07
Asymchem Laboratories Profit Rises 19% in 2025
Norges Bank Increases Stake in Asymchem Laboratories by 85,300 Shares at HK$98.94 Each
Stock News  ·  04-20 19:40
Norges Bank Increases Stake in Asymchem Laboratories by 85,300 Shares at HK$98.94 Each
Asymchem Tianjin publishes 2025 annual report
Reuters  ·  04-20 19:32
Asymchem Tianjin publishes 2025 annual report
Asymchem Laboratories held extraordinary general meeting to vote on share repurchase, articles changes
Reuters  ·  04-17
Asymchem Laboratories held extraordinary general meeting to vote on share repurchase, articles changes
Asymchem Laboratories Expands TIDES Production Capacity, Enhancing Drug Service Capabilities
Deep News  ·  04-16
Asymchem Laboratories Expands TIDES Production Capacity, Enhancing Drug Service Capabilities
J.P. Morgan Increases Stake in Asymchem by 95,600 Shares at HK$97.68 Per Share
Deep News  ·  04-14
J.P. Morgan Increases Stake in Asymchem by 95,600 Shares at HK$97.68 Per Share
Asymchem schedules board meeting to review first-quarter results
Reuters  ·  04-13
Asymchem schedules board meeting to review first-quarter results
Norges Bank Reduces Stake in Asymchem by 263,200 Shares at HK$104.64 Each
Stock News  ·  04-08
Norges Bank Reduces Stake in Asymchem by 263,200 Shares at HK$104.64 Each
Bocom International Maintains Buy Rating on Asymchem, Raises Target Price to HK$123.2
Deep News  ·  04-03
Bocom International Maintains Buy Rating on Asymchem, Raises Target Price to HK$123.2
Asymchem Laboratories Shares Experience Abnormal Trading Fluctuations, No Undisclosed Matters
Stock News  ·  04-01
Asymchem Laboratories Shares Experience Abnormal Trading Fluctuations, No Undisclosed Matters
Robust CXO Earnings Boost Performance: Huabao Fund's HK Connect Medical ETF and Medical ETF Rise Up to 2%
Deep News  ·  03-31
Robust CXO Earnings Boost Performance: Huabao Fund's HK Connect Medical ETF and Medical ETF Rise Up to 2%
Asymchem Laboratories Reports Annual Profit Growth of 19.35%
Stock News  ·  03-30
Asymchem Laboratories Reports Annual Profit Growth of 19.35%
Asymchem Laboratories proposes final dividend of RMB 13 per 10 shares
Reuters  ·  03-30
Asymchem Laboratories proposes final dividend of RMB 13 per 10 shares
Asymchem FY25 net profit climbs 19.35% to RMB 1.1 billion; revenue rises to RMB 6.7 billion
Reuters  ·  03-30
Asymchem FY25 net profit climbs 19.35% to RMB 1.1 billion; revenue rises to RMB 6.7 billion
BRIEF-Asymchem Laboratories (Tianjin) 2025 Net Profit Up 19.4% Y/Y
Reuters  ·  03-30
BRIEF-Asymchem Laboratories (Tianjin) 2025 Net Profit Up 19.4% Y/Y
Schroders PLC Increases Stake in Asymchem Laboratories with 88,500 Shares Purchase
Stock News  ·  03-30
Schroders PLC Increases Stake in Asymchem Laboratories with 88,500 Shares Purchase
Asymchem Laboratories Tianjin H shareholders vote on proxy appointments; meeting set for April 17, 2026
Reuters  ·  03-25
Asymchem Laboratories Tianjin H shareholders vote on proxy appointments; meeting set for April 17, 2026
Asymchem Laboratories Tianjin schedules board meeting to approve annual results and consider final dividend
Reuters  ·  03-16
Asymchem Laboratories Tianjin schedules board meeting to approve annual results and consider final dividend
Asymchem to Repurchase and Cancel Restricted A-Shares Under 2025 Equity Incentive Plan
Stock News  ·  03-13
Asymchem to Repurchase and Cancel Restricted A-Shares Under 2025 Equity Incentive Plan
Asymchem Laboratories Tianjin to Cancel 61,000 Restricted A Shares in Capital Reduction
Reuters  ·  03-13
Asymchem Laboratories Tianjin to Cancel 61,000 Restricted A Shares in Capital Reduction

Introduction

Company Name.
凯莱英医药集团(天津)股份有限公司
Industry:
医药制造业
Listing Date:
2016-11-18
Main Business:
　　凯莱英医药集团(天津)股份有限公司的主营业务是为国内外制药公司、生物技术公司提供药品全生命周期的一站式服务。公司的主要产品是小分子CDMO解决方案、新兴业务。凯莱英生物AsymBio偶联药物开发平台成功入围第12届WorldADCAwards“BestADCPlatformTechnology”奖项，印证了凯莱英生物在全球抗体偶联药物CDMO领域的卓越地位。
Issue price:
30.53